First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders
December 14, 2023 09:15 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma,” “First Wave” or the “Company”), a clinical-stage biopharmaceutical company...
First Wave BioPharma to Participate in BIO Partnering @JPM During “J.P. Morgan Week 2024”
December 06, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference
December 05, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
September 14, 2023 06:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market
June 13, 2023 12:50 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
March 13, 2023 08:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Participate in ‘Fireside Chat’ at the 35th Annual Roth Conference
February 28, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Regains Compliance With Nasdaq’s Minimum Bid Price Requirement
February 07, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Announces Distribution of Series F Preferred Stock to Holders of Its Common Stock
November 25, 2022 17:45 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering
October 06, 2022 21:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...